CompletedEUCTR 2009-014045-92
Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomis...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Czechia · Estonia and 3 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 540
- Sponsor
- Institut de Recherches Internationales Servier
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France, Czechia, Estonia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2009-014045-92
- Official title
Show the full official title
Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomis...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedCzechia · Estonia · Finland
2 more locations
- France
- Sweden
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier, a research institute.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
